Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2919)
All Articles published online
|
Dec 15, 2002 (publication date) through Nov 3, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Han LH, Sun WS, Ma CH, Zhang LN, Liu SX, Zhang Q, Gao LF, Chen YH. Detection of soluble TRAIL in HBV infected patients and its clinical implications. World J Gastroenterol 2002; 8(6): 1077-1080 [PMID: 12439929 DOI: 10.3748/wjg.v8.i6.1077] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v8/i6/1077.htm |
| Number | Citing Articles |
| 1 |
Jong Weon Choi. Associations of Fas (CD95), tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), and biochemical manifestations in elderly persons. Clinica Chimica Acta 2006; 365(1-2): 113 doi: 10.1016/j.cca.2005.08.004
|
| 2 |
Gu-Choul Shin, Hong Seok Kang, Ah Ram Lee, Kyun-Hwan Kim. Hepatitis B virus–triggered autophagy targets TNFRSF10B/death receptor 5 for degradation to limit TNFSF10/TRAIL response. Autophagy 2016; 12(12): 2451 doi: 10.1080/15548627.2016.1239002
|
| 3 |
Harmeet Malhi, Gregory J. Gores. Schiff's Diseases of the Liver. 2011; : 216 doi: 10.1002/9781119950509.ch8
|
| 4 |
A Piekarska, R Kubiak, A Omulecka, W Szymczak, J Piekarski. Expression of tumour necrosis factor‐related apoptosis‐inducing ligand and caspase‐3 in relation to grade of inflammation and stage of fibrosis in chronic hepatitis C. Histopathology 2007; 51(5): 597 doi: 10.1111/j.1365-2559.2007.02863.x
|
| 5 |
Harald Wajant. Molecular Mode of Action of TRAIL Receptor Agonists—Common Principles and Their Translational Exploitation. Cancers 2019; 11(7): 954 doi: 10.3390/cancers11070954
|
| 6 |
Harmeet Malhi, Gregory J. Gores, John J. Lemasters. Apoptosis and Necrosis in the Liver: A Tale of Two Deaths?. Hepatology 2006; 43(Supplement 1): S31 doi: 10.1002/hep.21062
|
| 7 |
Henning Walczak, Ronald Koschny, Daniela Willen, Manuela B. Schader, Jaromir Sykora, Tom M. Ganten, Tobias L. Haas. Apoptosis and Cancer Therapy. 2006; : 31 doi: 10.1002/9783527619665.ch2
|
| 8 |
Marco A Cassatella, Veronica Huber, Federica Calzetti, Daniela Margotto, Nicola Tamassia, Giuseppe Peri, Alberto Mantovani, Licia Rivoltini, Cristina Tecchio. Interferon-activated neutrophils store a TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) intracellular pool that is readily mobilizable following exposure to proinflammatory mediators. Journal of Leukocyte Biology 2005; 79(1): 123 doi: 10.1189/jlb.0805431
|
| 9 |
Xiaohua Yan, Liyun Xu, Jianni Qi, Xiaohong Liang, Chunhong Ma, Chun Guo, Lining Zhang, Wensheng Sun, Jiyun Zhang, Xiaoyi Wei, Lifen Gao. sTRAIL levels and TRAIL gene polymorphisms in Chinese patients with fatty liver disease. Immunogenetics 2009; 61(8): 551 doi: 10.1007/s00251-009-0389-4
|
| 10 |
Angela Kuhla, Michael Thrum, Ute Schaeper, Volker Fehring, Ulf Schulze-Topphoff, Kerstin Abshagen, Brigitte Vollmar. Liver-specific Fas silencing prevents galactosamine/lipopolysaccharide-induced liver injury. Apoptosis 2015; 20(4): 500 doi: 10.1007/s10495-015-1088-2
|
| 11 |
Nicoletta Pelli, Francesco Torre, Andrea Delfino, Monica Basso, Antonino Picciotto. Soluble Tumor Necrosis Factor-Related Ligand (sTRAIL) Levels and Kinetics During Antiviral Treatment in Chronic Hepatitis C. Journal of Interferon & Cytokine Research 2006; 26(2): 119 doi: 10.1089/jir.2006.26.119
|
| 12 |
|
| 13 |
Shi-Jun Zheng, Pu Wang, Galit Tsabary, Youhai H. Chen. Critical roles of TRAIL in hepatic cell death and hepatic inflammation. Journal of Clinical Investigation 2004; 113(1): 58 doi: 10.1172/JCI200419255
|
| 14 |
Federico Monti, Federica Perazza, Laura Leoni, Bernardo Stefanini, Silvia Ferri, Francesco Tovoli, Guido Zavatta, Fabio Piscaglia, Maria Letizia Petroni, Federico Ravaioli. RANK–RANKL–OPG Axis in MASLD: Current Evidence Linking Bone and Liver Diseases and Future Perspectives. International Journal of Molecular Sciences 2024; 25(17): 9193 doi: 10.3390/ijms25179193
|
| 15 |
Eiji Mori, Mayumi Thomas, Kazuhiro Motoki, Shiro Kataoka. Distinct function of monoclonal antibody to TRAIL‐R2 as potentiator or inhibitor of the ligand TRAIL‐induced apoptosis. FEBS Letters 2005; 579(24): 5379 doi: 10.1016/j.febslet.2005.09.009
|
| 16 |
Harmeet Malhi, Gregory J. Gores. Schiff's Diseases of the Liver. 2017; : 200 doi: 10.1002/9781119251316.ch7
|
| 17 |
Juan Du, Lei Wang, Jianjun Han, Lifen Gao, Chunhong Ma, Xiaohong Liang. Serum soluble death receptor 5 concentration in patients with chronic hepatitis B is associated with liver damage and viral antigen level. Clinical Biochemistry 2012; 45(10-11): 845 doi: 10.1016/j.clinbiochem.2012.04.007
|
| 18 |
Ingrid Herr, Peter Schemmer, Markus W. Büchler. On the TRAIL to therapeutic intervention in liver disease. Hepatology 2007; 46(1): 266 doi: 10.1002/hep.21740
|
| 19 |
Juan Li, Fan-Wei Liu, Dong-Bo Wu, En-Qiang Chen, Xiang-Jun Chen, Shou-Chun Chen, Cong Liu, Lian-Shan Zhao, Hong Tang, Tao-You Zhou. TRAIL inhibits HBV replication and expression by down-regulating liver-enriched transcription factors. Arab Journal of Gastroenterology 2020; 21(3): 169 doi: 10.1016/j.ajg.2020.05.002
|
| 20 |
Shi-Jun Zheng, Pu Wang, Galit Tsabary, Youhai H. Chen. Critical roles of TRAIL in hepatic cell death and hepatic inflammation. Journal of Clinical Investigation 2004; 113(1): 58 doi: 10.1172/JCI19255
|
| 21 |
N Pelli, A Floreani, F Torre, A Delfino, A Baragiotta, P Contini, M Basso, A Picciotto. Soluble apoptosis molecules in primary biliary cirrhosis: analysis and commitment of the Fas and tumour necrosis factor-related apoptosis-inducing ligand systems in comparison with chronic hepatitis C. Clinical and Experimental Immunology 2007; 148(1): 85 doi: 10.1111/j.1365-2249.2006.03293.x
|
| 22 |
Delphine Mérino, Najoua Lalaoui, Alexandre Morizot, Eric Solary, Olivier Micheau. TRAIL in cancer therapy: present and future challenges. Expert Opinion on Therapeutic Targets 2007; 11(10): 1299 doi: 10.1517/14728222.11.10.1299
|
| 23 |
Yukiko Saitou, Katsuya Shiraki, Hiroyuki Fuke, Tomoko Inoue, Kazumi Miyashita, Yutaka Yamanaka, Yumi Yamaguchi, Norihik Yamamoto, Keiichi Ito, Kazushi Sugimoto, Takeshi Nakano. Involvement of tumor necrosis factor–related apoptosis-inducing ligand and tumor necrosis factor–related apoptosis-inducing ligand receptors in viral hepatic diseases. Human Pathology 2005; 36(10): 1066 doi: 10.1016/j.humpath.2005.07.019
|
| 24 |
Guillaume Jacquemin, Sarah Shirley, Olivier Micheau. Combining naturally occurring polyphenols with TNF-related apoptosis-inducing ligand: a promising approach to kill resistant cancer cells?. Cellular and Molecular Life Sciences 2010; 67(18): 3115 doi: 10.1007/s00018-010-0407-6
|
| 25 |
Arzu Didem Yalcin, Atil Bisgin, Aysegul Kargi, Reginald M. Gorczynski. Serum-soluble TRAIL levels in patients with severe persistent allergic asthma: Its relation to omalizumab treatment. Medical Science Monitor 2012; 18(3): PI11 doi: 10.12659/MSM.882504
|
| 26 |
Qian Chen, Pu Wang, Qingmei Zhang, Meng Xia, Guizhong Zhang, Junxin Li, Enyun Shen, Youhai H. Chen, Xiaochun Wan. Preclinical studies of a death receptor 5 fusion protein that ameliorates acute liver failure. Journal of Molecular Medicine 2019; 97(9): 1247 doi: 10.1007/s00109-019-01813-w
|
| 27 |
A. Shi, X. Zhang, F. Xiao, L. Zhu, W. Yan, M. Han, X. Luo, T. Chen, Q. Ning. CD56bright natural killer cells induce HBsAg reduction via cytolysis and cccDNA decay in long‐term entecavir‐treated patients switching to peginterferon alfa‐2a. Journal of Viral Hepatitis 2018; 25(11): 1352 doi: 10.1111/jvh.12946
|
| 28 |
Samuel H. Sigal, Aftab Ala, Katya Ivanov, Sabera Hossain, Carol Bodian, Thomas D. Schiano, Albert D. Min, Henry C. Bodenheimer, Swan N. Thung. Histopathology and clinical correlates of end-stage hepatitis B cirrhosis: A possible mechanism to explain the response to antiviral therapy. Liver Transplantation 2005; 11(1): 82 doi: 10.1002/lt.20328
|
| 29 |
Atil Bisgin, Aysegul Kargi, Arzu D Yalcin, Cigdem Aydin, Deniz Ekinci, Burhan Savas, Salih Sanlioglu. Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer. BMC Cancer 2012; 12(1) doi: 10.1186/1471-2407-12-58
|
| 30 |
İlhan Yaylım, Nazlı Ezgi Ozkan, Saime Turan, Gurbet Korkmaz, Yemliha Yıldız, Canan Cacina, Bahar Toptaş, Soykan Arıkan. sTRAIL Serum Levels and TRAIL 1595 Genotypes: Associations with Progress and Prognosis of Colorectal Carcinoma. Journal of Cancer Therapy 2012; 3(06): 941 doi: 10.4236/jct.2012.326120
|
| 31 |
Fangfang Liu, Wen Cheng, Xiaolei Bi, Yun Zhang, Yuxia Zhao, Fan Jiang. Stage‐dependent effects of exogenous TRAIL on atherogenesis: role of ER stress‐mediated sensitization of macrophage apoptosis. Clinical and Experimental Pharmacology and Physiology 2016; 43(5): 543 doi: 10.1111/1440-1681.12561
|
| 32 |
Kamal Shaik Fakiruddin, Nadiah Ghazalli, Moon Nian Lim, Zubaidah Zakaria, Syahril Abdullah. Mesenchymal Stem Cell Expressing TRAIL as Targeted Therapy against Sensitised Tumour. International Journal of Molecular Sciences 2018; 19(8): 2188 doi: 10.3390/ijms19082188
|
| 33 |
Darshpreet Kaur, Rahul Deshmukh. Clinical Perspectives and Targeted Therapies in Apoptosis. 2021; : 23 doi: 10.1016/B978-0-12-815762-6.00002-0
|
| 34 |
Wei Jiang, Dong-Bo Wu, Si-Yu Fu, En-Qiang Chen, Hong Tang, Tao-You Zhou. Insight into the role of TRAIL in liver diseases. Biomedicine & Pharmacotherapy 2019; 110: 641 doi: 10.1016/j.biopha.2018.12.004
|
| 35 |
Fan-wei Liu, Dong-bo Wu, En-qiang Chen, Cong Liu, Li Liu, Shou-chun Chen, Dao-yin Gong, Lian-san Zhao, Hong Tang, Tao-you Zhou. Expression of TRAIL in liver tissue from patients with different outcomes of HBV infection. Clinics and Research in Hepatology and Gastroenterology 2013; 37(3): 269 doi: 10.1016/j.clinre.2012.09.009
|
| 36 |
Akiko Eguchi, Alexander Wree, Ariel E. Feldstein. Biomarkers of liver cell death. Journal of Hepatology 2014; 60(5): 1063 doi: 10.1016/j.jhep.2013.12.026
|
| 37 |
Aysegul Verim, Saime Turan, Ammad Ahmad Farooqi, Ozlem Timirci Kahraman, Cigdem Tepe-Karaca, Yemliha Yildiz, Baris Naiboglu, Nazli Ezgi Ozkan, Arzu Ergen, Gulbu Aydinoglu Isitmangil, Ilhan Yaylim. Association between Laryngeal Squamous Cell Carcinoma and Polymorphisms in Tumor Necrosis Factor Related Apoptosis Induce Ligand (TRAIL), TRAIL Receptor and sTRAIL Levels. Asian Pacific Journal of Cancer Prevention 2015; 15(24): 10697 doi: 10.7314/APJCP.2014.15.24.10697
|
| 38 |
Anvar Soleimani, Houshang Rafatpanah, Amin Reza Nikpoor, Mehrdad Kargari, Daryoush Hamidi Alamdari. Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Gene Polymorphisms and Hepatitis B Virus Infection. Jundishapur Journal of Microbiology 2015; 8(11) doi: 10.5812/jjm.23578
|
| 39 |
Nina-Beate Liabakk, Terje Espevik. TRAIL (TNF-Related Apoptosis-Inducing Ligand). Vitamins & Hormones 2004; 67: 65 doi: 10.1016/S0083-6729(04)67005-1
|
| 40 |
Fang Fang Liu, Xiao Wu, Yun Zhang, Yan Wang, Fan Jiang, Shawn B. Bratton. TRAIL/DR5 Signaling Promotes Macrophage Foam Cell Formation by Modulating Scavenger Receptor Expression. PLoS ONE 2014; 9(1): e87059 doi: 10.1371/journal.pone.0087059
|